Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. - Wikidata - wikimedia - TriplyDB

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

http://www.wikidata.org/entity/Q39719120

about

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases Jakpot! New small molecules in autoimmune and inflammatory diseases Shared epitope-antagonistic ligands: a new therapeutic strategy in mice with erosive arthritis.Whole-body deletion of LPS-induced TNF-α factor (LITAF) markedly improves experimental endotoxic shock and inflammatory arthritis A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.Selective JAK inhibitors in development for rheumatoid arthritis.Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age.Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate.A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis.JAK Kinases in Health and Disease: An Update Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study.The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells.Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance.Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis.Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors.Th17-cytokine blockers as a new approach for treating inflammatory bowel disease.Are Th17 cells an appropriate new target in the treatment of rheumatoid arthritis?Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.New JAK2 inhibitors for myeloproliferative neoplasms.A decade of the human genome sequence--how does the medicinal chemist benefit?Direct and indirect regulatory mechanisms in TH17 cell differentiation and functions.Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?Targeting kinases for the treatment of inflammatory diseases.Targeting the Th17 pathway in psoriasis.Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.

P2860

Q26765028-7E90293B-8126-4EEE-8E8A-EE6707006279 Q26774874-27FD59FC-0DF8-4871-B58B-5A9FA763AC9E Q26775111-A256AE45-A817-4840-ACEB-5E81A22EE519 Q27001957-745029FA-B5C8-42C0-B419-9EF1C1C0A389 Q27339594-88FE64A8-B53A-47BD-B18B-49CC3DCFE43D Q28511199-7E4DE085-71C7-44A9-AB33-FFAC43D4F4AC Q28552367-38CA5EDA-5D13-4B69-9432-8BD9BB1C98AA Q33988247-466EF6D8-C1E1-4604-B0DD-1E512970E012 Q34169114-93B6E84E-1440-44AB-895B-7679B5AE435C Q34276089-6F6BEE2C-9247-48E7-9D82-6A542D16A118 Q34419615-615EB360-48CE-4BE7-8493-2046C83EA404 Q34502046-E228106D-996C-4029-9F02-CC343B8E0076 Q34502049-5ADB97A8-5567-4A0B-B40F-E34F01A0FAC6 Q35048395-3BDC1C4D-F28A-4B9F-B3B3-BA7ADC7AA1E1 Q35092982-51EF7873-02A0-4A7E-B153-1A436611BB4F Q35093044-713B6ADA-7B13-4C1F-8ED9-D117F262E1BA Q35553626-18AA6451-E930-4361-A1F1-4229C106520B Q35834909-E4C6BB04-1061-497A-99FD-EB81CB849944 Q36285745-E6828DC1-B778-4D3D-950A-9CFDCA53086D Q36361686-B9FE2076-EFD5-4259-81E1-E14BAA117BDB Q36404704-31E199A3-DC54-48EA-A7C7-F5A77DBBC83A Q36506677-6192B7C6-245F-4DAD-8F32-78B44CBE6C9C Q36912333-89927B53-6403-43DA-B07C-E1DA7C4E90CB Q37039005-1F187926-A9A6-4939-8865-8343605572BA Q37224431-178C5647-A8B0-4D80-9958-422F9129F082 Q37603419-271209B8-833C-4711-BB04-AD2F443177B5 Q37708936-4F607430-3505-4FBC-993E-9239A8A560A8 Q37725753-352C4A46-0FAB-4705-8626-6AF6081B31BA Q37813138-F07F45B8-217F-4E95-9E65-098C1357119E Q37821982-649F7A91-BC1B-4299-8CF4-D37F636A5C6E Q37833893-88AE753A-84BC-4555-8C74-2025DDD9BE20 Q37869152-445A9F51-89D2-4ED7-8951-D75F1BE16797 Q37968558-08E05CF5-8A7F-45ED-B96C-A507448D9E41 Q37977126-8613E8C4-365E-41FA-825E-3E721100985F Q37998574-63ED077D-98C0-45FA-808E-52E8DD947A72 Q38028572-BB40A90A-3B0E-4D74-B9B2-588245569F56 Q38042048-A29A2160-E083-4310-A5A9-A540B0F0B04C Q38077992-A1EF7A61-3F79-45CF-B4CA-6CD374461086 Q38081267-0AD762D0-831A-4DF5-8A3C-259327DB3A11 Q38100790-19A53A57-563C-412A-8823-DF7CE5C1E3E5

P2860

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

http://www.wikidata.org/entity/Q39719120

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Selective inhibition of JAK1 a ...... haracterization of INCB028050.

@en

Selective inhibition of JAK1 a ...... haracterization of INCB028050.

@nl

type

label

Selective inhibition of JAK1 a ...... haracterization of INCB028050.

@en

Selective inhibition of JAK1 a ...... haracterization of INCB028050.

@nl

prefLabel

Selective inhibition of JAK1 a ...... haracterization of INCB028050.

@en

Selective inhibition of JAK1 a ...... haracterization of INCB028050.

@nl

P1433

Q39719120-D301E3B7-60B9-4352-9757-8D31EFE23E1A

P1476

Q39719120-DD6B1946-0419-4B08-B152-A1E19B85AD1B

P2093

Q39719120-13385F93-8F21-4A67-AAB5-42640F102470

Q39719120-1A53A63A-F8CA-4E3D-A9B5-A17FAAD634C9

Q39719120-2DA08F3D-5E7D-43E3-9BEC-09B0EDDCDB88

Q39719120-2E116CCD-CF78-47A4-AFFA-931C1B2879C7

Q39719120-375C4BCF-DC13-479C-8976-BE96ADD79ACA

Q39719120-4B2ECD3F-FFD6-4524-A15E-5E4200DA0672

Q39719120-4CA801A1-BB47-42BE-85EE-5766B91B2C12

Q39719120-4DFF1105-2878-432B-8475-E95EDA81D80E

Q39719120-5862ADE2-AB75-4619-A397-26300FDF2769

Q39719120-65D92EC0-1DE8-4FB4-9A29-B0B9E1287F20

P304

Q39719120-A607F519-680C-4285-9C7E-B12ACACD7E9A

P31

Q39719120-4C179793-1D86-4964-9E72-2A29DD20590D

P356

Q39719120-DE103829-C13C-411A-B2CF-C049C4AB6204

P407

Q39719120-9352282E-9A12-4B65-B893-EE334918E1B0

P433

Q39719120-69A1068F-2968-433F-AA56-5A4C92B28CEF

P478

Q39719120-B2516067-255B-4CD1-A5DE-AF55B674BBD5

P577

Q39719120-070424B1-34F5-4097-B1AE-B75032317F0D

P5875

Q39719120-72010C1C-5F18-4572-A4AD-5D875FD3873B

P698

Q39719120-A4B5F3F2-6900-49A7-A7AD-ADABCC02E9CD

P356

JIMMUNOL.0902819

P1433

Journal of Immunology

P1476

Selective inhibition of JAK1 a ...... haracterization of INCB028050.

@en

P2093

Beth Thomas

http://www.w3.org/2001/XMLSchema#string

Brian Metcalf

http://www.w3.org/2001/XMLSchema#string

Greg Hollis

http://www.w3.org/2001/XMLSchema#string

Jack Shi

http://www.w3.org/2001/XMLSchema#string

James D Rodgers

http://www.w3.org/2001/XMLSchema#string

Jordan S Fridman

http://www.w3.org/2001/XMLSchema#string

Jun Li

http://www.w3.org/2001/XMLSchema#string

Kris Vaddi

http://www.w3.org/2001/XMLSchema#string

Margaret F Favata

http://www.w3.org/2001/XMLSchema#string

Maryanne B Covington

http://www.w3.org/2001/XMLSchema#string

P304

5298-5307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.0902819

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

184

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42975825

http://www.w3.org/2001/XMLSchema#string

P698

20363976

http://www.w3.org/2001/XMLSchema#string